Chronolife, an artificial intelligence company specializing in digital health, announced the commercial launch of Nexkin, a groundbreaking washable smart T-shirt that monitors six key physiological parameters to enable prevention, risk reduction, and remote monitoring. The announcement follows Nexkin receiving the CE (Conformité Européenne) mark, certifying it as meeting all safety and performance requirements for sale in the European Union, and came as Chronolife announced the closing of new fundraising to support its commercial and industrial phase.

The Nexkin platform uses cutting-edge wearable electronics to integrate 10 biometric scanners into a comfortable, machine-washable T-shirt capable of continuously recording a user’s electrocardiogram, abdominal and thoracic breathing, body temperature, physical activity, and pulmonary impedance. Data from the shirt is transmitted via Bluetooth to the user’s smartphone, where data from multiple sensors can be integrated using Chronolife’s unique HOTS (Hierarchy Of event-based Time Surfaces) algorithms to deliver accurate and actionable health insights, which can subsequently be downloaded or transferred to secure servers for review by health professionals.

Comfortable enough for round-the-clock use, and combining a 24-hour battery life with the ability to fully recharge in just a few hours, Chronolife’s Nexkin technology’s combination of AI-powered real-time analytics and next-generation wearable sensors has the potential to revolutionize fields including aging-in-place, senior care, occupational health and safety, sports rehabilitation, military training, and performance management.

“The Nexkin T-shirt makes accurate, unobtrusive continuous health monitoring both affordable and convenient across a wide range of industries and functionalities, from pharmaceutical testing to senior care,” said Laurent Vandebrouck, CEO of Chronolife. “By combining wearable electronics with advanced AI-powered analytics, we’re delivering biometric monitoring capabilities that will revolutionize the way researchers and healthcare professionals will eventually interact with patients.”

The commercial launch of Nexkin will allow Chronolife’s clients and partners to explore ways to deploy and test the technology in clinical and other settings, including:

  • Healthcare organizations and professionals using Nexkin will be able to continuously monitor users’ physiological markers, detect abnormalities, and intervene promptly.
  • Insurance providers incorporating Nexkin into outpatient preventative and support services for elderly users, increasing their independence and reducing treatment costs.
  • Pharmaceutical companies testing and validating Nexkin as a means of boosting the accuracy and utility of clinical trials and therapeutic efficacy programs.

Source: Chronolife